Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer

Abstract

Background:The purpose of this study was to evaluate the efficacy of superselective cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with the squamous cell carcinoma of maxillary sinus (SCC-MS).Methods:Between 1999 and 2010, 54 patients were given superselective intra-arterial infusions of cisplatin (100–120 mg m−2 per week) with simultaneous intra-venous infusions of thiosulfate to neutralise cisplatin toxicity and conventional radiotherapy (65–70 Gy).Results:One patient (1.9%) was diagnosed with T2, 14 (25.9%) with T3, 27 (50%) with T4a, and 12 (22.2%) with T4b disease. Lymph-node involvement was present in 12 patients (22.2%). During the median follow-up period of 6.4 years, the 5-year local progression-free and overall survival rates were 65.8 and 67.9% for all patients, respectively. No patient died as a result of treatment toxicity or experienced a cerebrovascular accident. Osteonecrosis (n=5), brain necrosis (n=1), and ocular/visual problems (n=14) were observed as late adverse reactions.Conclusion:We have shown excellent overall survival and local progression-free rate in SCC-MS patients treated by RADPLAT with acceptable rates of acute and late toxicity. A multi-institutional trial is needed to prove that this strategy is a feasible and effective approach for the treatment of SCC-MS.

Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer

“…As mentioned elsewhere, their report made no mention of the angiographic technique used or the adequacy of cisplatin infusion into the tumor-feeding artery [7]. Further, HPC patients comprised only a small subgroup of the total study population, and this trial targeted unresectable patients, which meant that it could not assess organ preservation [5].…”

“…However, a group in the Netherlands reported a multicenter, randomized phase 3 trial, in which HPC was performed for 19% of patients in the intra-arterial group and 18% of those in the intravenous group, and concluded that intra-arterial chemoradiation was not superior to intravenous chemoradiation [6]. However, as several points in association with this trial remain controversial [5,7], we decided to retrospectively examine the indications for RADPLAT, with a particular focus on TN stage, in patients with HPC.…”

Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience

“…Eight patients (32%) were treated with radiotherapy and concomitant intra-arterial chemotherapy (RADPLAT). The treatment protocol for IV-CRT and RADPLAT has been described elsewhere [3][4][5][6]. …”

Residual tumour detection in post-treatment granulation tissue by using advanced diffusion models in head and neck squamous cell carcinoma patients

“…In particular, the use of super-selective arterial infusions of cisplatin with concomitant radiotherapy has become popular for head and neck SCC because of its higher local control rate in advanced cases, especially those in the nasal or sinonasal cavity, oral cavity and pharynx SCCs [2][3][4].…”